Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin extension study in drug-naive T2D
NCT00300287Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2006
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Vildagliptin with Placebo (2 arms). Primary endpoint: Change from baseline in HbA1c at 108 weeks. Started Feb 2006; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00300287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00300287.